Application | Comment | Organism |
---|---|---|
pharmacology | use of benzyloxycarbonyl-L-phenylalanyl-alanine-fluoromethylketone for inhibition of cathepsin-B seems a viable therapeutic strategy in TNF-alpha-mediated acute lung damage | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
benzyloxycarbonyl-L-phenylalanyl-alanine-fluoromethylketone | inhibits cathepsin B, treatment stimulates proliferation of type-II pneumocytes and improves degenerative alterations in injured lung occurring with liver injury induced by D-GalN/TNF-alpha, overview | Mus musculus |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
lysosome | cathepsin B is expressed ubiquitously and represents the major portion of lysosomal enzymes | Mus musculus | 5764 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
male BALB/c mice | - |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
bronchial epithelial cell | - |
Mus musculus | - |
fibroblast | - |
Mus musculus | - |
liver | - |
Mus musculus | - |
lung | mesothelial cells and fibroblasts | Mus musculus | - |
mesothelium | - |
Mus musculus | - |
additional information | cathepsin B is expressed ubiquitously and represents the major portion of lysosomal enzymes | Mus musculus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
N-benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O | - |
Mus musculus | N-benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin | - |
? |
General Information | Comment | Organism |
---|---|---|
metabolism | cathepsin B is involved in TNF-alpha-induced signal transduction pathways in lung cells | Mus musculus |
physiological function | cathepsin B acts as the main executor of caspase dependent or independent cell death in major organs including the liver, kidney, and lungs | Mus musculus |